Ge Long Hui A P P·2025-08-14 06:44Core Viewpoint - Sanchin Medical is experiencing steady growth in its business for the first half of 2025, with revenue growth accelerating quarter by quarter [1] Revenue Performance - In Q1 2025, the company achieved revenue of 361 million yuan, representing a year-over-year increase of 8.88% - In Q2 2025, revenue reached 400 million yuan, showing a year-over-year growth of 12.65% [1] Regional Analysis - Domestic revenue for the first half of 2025 was 574 million yuan, reflecting a slight year-over-year decline of 0.15% due to price reductions from centralized procurement - The company maintained its market share by exchanging price for volume, and the long-term demand in the domestic blood purification market is expected to be substantial due to the implementation of policies for dialysis centers in county areas [1] International Growth - Overseas revenue amounted to 187 million yuan, marking a significant year-over-year increase of 67.3%, with its revenue contribution rising to 24.6% - The company is accelerating its internationalization process by completing product registrations in countries such as Indonesia, Peru, and Mexico, which is expected to drive future growth [1] Business Outlook - The core business of blood purification continues to grow rapidly, supported by a rich pipeline of products and strong growth momentum [1]